LT4005592T - Viriono tipo tiekimo dalelės, skirtos savaime besireplikuojančioms rnr molekulėms - Google Patents
Viriono tipo tiekimo dalelės, skirtos savaime besireplikuojančioms rnr molekulėmsInfo
- Publication number
- LT4005592T LT4005592T LTEP21204155.2T LT21204155T LT4005592T LT 4005592 T LT4005592 T LT 4005592T LT 21204155 T LT21204155 T LT 21204155T LT 4005592 T LT4005592 T LT 4005592T
- Authority
- LT
- Lithuania
- Prior art keywords
- virion
- self
- rna molecules
- replicating rna
- delivery particles
- Prior art date
Links
- 239000002245 particle Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36141—Use of virus, viral particle or viral elements as a vector
- C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US36182810P | 2010-07-06 | 2010-07-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
LT4005592T true LT4005592T (lt) | 2023-01-10 |
Family
ID=44629863
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LTEP11741348.4T LT2590676T (lt) | 2010-07-06 | 2011-07-06 | Viriono tipo išnešiojančios dalelės, skirtos besireplikuojančioms rnr molekulėms |
LTEP21204155.2T LT4005592T (lt) | 2010-07-06 | 2011-07-06 | Viriono tipo tiekimo dalelės, skirtos savaime besireplikuojančioms rnr molekulėms |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LTEP11741348.4T LT2590676T (lt) | 2010-07-06 | 2011-07-06 | Viriono tipo išnešiojančios dalelės, skirtos besireplikuojančioms rnr molekulėms |
Country Status (22)
Country | Link |
---|---|
US (2) | US11291635B2 (lt) |
EP (4) | EP3115061A1 (lt) |
JP (1) | JP6061849B2 (lt) |
CN (2) | CN106421773A (lt) |
AU (1) | AU2011276232B2 (lt) |
BR (1) | BR112013000392B8 (lt) |
CA (1) | CA2804494A1 (lt) |
CY (1) | CY1118080T1 (lt) |
DK (1) | DK2590676T3 (lt) |
ES (2) | ES2934240T3 (lt) |
FI (1) | FI4005592T3 (lt) |
HR (2) | HRP20221522T1 (lt) |
HU (2) | HUE031485T2 (lt) |
LT (2) | LT2590676T (lt) |
MX (1) | MX342608B (lt) |
PL (2) | PL2590676T3 (lt) |
PT (2) | PT2590676T (lt) |
RS (2) | RS55260B1 (lt) |
RU (1) | RU2013104890A (lt) |
SI (2) | SI2590676T1 (lt) |
SM (1) | SMT201600386B (lt) |
WO (1) | WO2012006376A2 (lt) |
Families Citing this family (168)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012006369A2 (en) | 2010-07-06 | 2012-01-12 | Novartis Ag | Immunisation of large mammals with low doses of rna |
CA2804494A1 (en) | 2010-07-06 | 2012-01-12 | Novartis Ag | Virion-like delivery particles for self-replicating rna molecules |
MX343410B (es) | 2010-07-06 | 2016-11-04 | Novartis Ag * | Emulsiones cationicas de agua en aceite. |
ES2770335T3 (es) | 2010-07-06 | 2020-07-01 | Glaxosmithkline Biologicals Sa | Administración de ARN para desencadenar múltiples vías inmunológicas |
PL2590626T3 (pl) | 2010-07-06 | 2016-04-29 | Glaxosmithkline Biologicals Sa | Liposomy z lipidami o korzystnej wartości pka do dostarczania rna |
EP2600901B1 (en) | 2010-08-06 | 2019-03-27 | ModernaTX, Inc. | A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof |
LT3981427T (lt) | 2010-08-31 | 2022-08-10 | Glaxosmithkline Biologicals S.A. | Pegilintos liposomos, skirtos imunogeną koduojančios rnr pristatymui |
HRP20221048T1 (hr) | 2010-08-31 | 2022-11-11 | Glaxosmithkline Biologicals Sa | Mali liposomi za isporuku rna koja kodira imunogen |
ES2737960T3 (es) | 2010-10-01 | 2020-01-17 | Modernatx Inc | Nucleósidos, nucleótidos y ácidos nucleicos modificados y sus usos |
MX363307B (es) | 2010-10-11 | 2019-03-20 | Novartis Ag Star | Plataformas para suministro de antigenos. |
AU2012236099A1 (en) | 2011-03-31 | 2013-10-03 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
TR201910686T4 (tr) | 2011-06-08 | 2019-08-21 | Translate Bio Inc | Mrna iletimine yönelik lipit nanopartikül bileşimleri ve yöntemler. |
CA2840989A1 (en) | 2011-07-06 | 2013-01-10 | Novartis Ag | Immunogenic combination compositions and uses thereof |
WO2013006837A1 (en) | 2011-07-06 | 2013-01-10 | Novartis Ag | Cationic oil-in-water emulsions |
EP3424495A1 (en) | 2011-07-06 | 2019-01-09 | GlaxoSmithKline Biologicals S.A. | Oil-in-water emulsions that contain nucleic acids |
EP2729126B1 (en) * | 2011-07-06 | 2020-12-23 | GlaxoSmithKline Biologicals SA | Liposomes having useful n:p ratio for delivery of rna molecules |
RU2628705C2 (ru) | 2011-08-31 | 2017-08-21 | Новартис Аг | Пегилированные липосомы для доставки кодирующей иммуноген рнк |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
EP3682905B1 (en) | 2011-10-03 | 2021-12-01 | ModernaTX, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
BR112014008694A2 (pt) * | 2011-10-11 | 2017-06-20 | Novartis Ag | moléculas de ácido nucleico policistrônico recombinante |
EP2791160B1 (en) | 2011-12-16 | 2022-03-02 | ModernaTX, Inc. | Modified mrna compositions |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
US9303079B2 (en) | 2012-04-02 | 2016-04-05 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
AU2013243948A1 (en) | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins associated with human disease |
AU2013243949A1 (en) | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of biologics and proteins associated with human disease |
MX2014015041A (es) | 2012-06-08 | 2015-06-17 | Shire Human Genetic Therapies | Administración pulmonar de arnm a células objetivo no pulmonares. |
US9512456B2 (en) | 2012-08-14 | 2016-12-06 | Modernatx, Inc. | Enzymes and polymerases for the synthesis of RNA |
EP4074834A1 (en) | 2012-11-26 | 2022-10-19 | ModernaTX, Inc. | Terminally modified rna |
CN109045294A (zh) * | 2013-01-10 | 2018-12-21 | 思齐乐 | 流感病毒免疫原性组合物及其应用 |
EP2946014A2 (en) | 2013-01-17 | 2015-11-25 | Moderna Therapeutics, Inc. | Signal-sensor polynucleotides for the alteration of cellular phenotypes |
WO2014159813A1 (en) | 2013-03-13 | 2014-10-02 | Moderna Therapeutics, Inc. | Long-lived polynucleotide molecules |
US10258698B2 (en) | 2013-03-14 | 2019-04-16 | Modernatx, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
LT2970948T (lt) | 2013-03-15 | 2019-03-25 | Glaxosmithkline Biologicals Sa | Rna gryninimo būdai |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
HRP20211563T1 (hr) | 2013-07-11 | 2022-01-07 | Modernatx, Inc. | Pripravci koji sadrže sintetske polinukleotide koji kodiraju proteine srodne crispr-u i sintetske sgrna, te postupci njihove uporabe |
US20160194625A1 (en) | 2013-09-03 | 2016-07-07 | Moderna Therapeutics, Inc. | Chimeric polynucleotides |
WO2015034925A1 (en) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Circular polynucleotides |
WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
CA2926218A1 (en) | 2013-10-03 | 2015-04-09 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
WO2015126477A1 (en) * | 2013-11-08 | 2015-08-27 | Tyrx, Inc. | Polymeric drug delivery system for treating surgical complications |
US10842859B2 (en) * | 2014-03-25 | 2020-11-24 | Yale University | Uses of parasite macrophage migration inhibitory factors |
BR112016024644A2 (pt) | 2014-04-23 | 2017-10-10 | Modernatx Inc | vacinas de ácido nucleico |
EP2974739A1 (en) | 2014-07-15 | 2016-01-20 | Novartis AG | RSVF trimerization domains |
EP3888676A1 (en) | 2014-06-13 | 2021-10-06 | GlaxoSmithKline Biologicals S.A. | Immunogenic combinations |
CA2955250A1 (en) | 2014-07-16 | 2016-01-21 | Moderna Therapeutics, Inc. | Chimeric polynucleotides |
EP3171895A1 (en) | 2014-07-23 | 2017-05-31 | Modernatx, Inc. | Modified polynucleotides for the production of intrabodies |
EP3061826A1 (en) | 2015-02-27 | 2016-08-31 | Novartis AG | Flavivirus replicons |
ES2746340T3 (es) | 2015-04-22 | 2020-03-05 | Curevac Ag | Composición que contiene ARN para el tratamiento de enfermedades tumorales |
EP3324979B1 (en) | 2015-07-21 | 2022-10-12 | ModernaTX, Inc. | Infectious disease vaccines |
US11364292B2 (en) | 2015-07-21 | 2022-06-21 | Modernatx, Inc. | CHIKV RNA vaccines |
PT3350157T (pt) | 2015-09-17 | 2022-03-18 | Modernatx Inc | Compostos e composições para administração intracelular de agentes terapêuticos |
US10849920B2 (en) | 2015-10-05 | 2020-12-01 | Modernatx, Inc. | Methods for therapeutic administration of messenger ribonucleic acid drugs |
EP3364981A4 (en) | 2015-10-22 | 2019-08-07 | ModernaTX, Inc. | VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS |
SG10201914006UA (en) * | 2015-10-22 | 2020-03-30 | Modernatx Inc | Respiratory syncytial virus vaccine |
EP3364950A4 (en) | 2015-10-22 | 2019-10-23 | ModernaTX, Inc. | VACCINES AGAINST TROPICAL DISEASES |
US20180303929A1 (en) * | 2015-10-22 | 2018-10-25 | Moderna TX, Inc. | Herpes simplex virus vaccine |
CA3002912A1 (en) * | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Nucleic acid vaccines for varicella zoster virus (vzv) |
CA3002819A1 (en) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Sexually transmitted disease vaccines |
EP3365007A4 (en) * | 2015-10-22 | 2019-07-03 | ModernaTX, Inc. | VACCINE AGAINST BROAD SPECTRUM INFLUENZA VIRUS |
EP3964200A1 (en) | 2015-12-10 | 2022-03-09 | ModernaTX, Inc. | Compositions and methods for delivery of therapeutic agents |
AU2016377681B2 (en) | 2015-12-22 | 2021-05-13 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of agents |
HRP20220525T1 (hr) | 2015-12-23 | 2022-05-27 | Modernatx, Inc. | Postupci uporabe polinukleotida koji kodiraju ligand ox40 |
WO2017120612A1 (en) | 2016-01-10 | 2017-07-13 | Modernatx, Inc. | Therapeutic mrnas encoding anti ctla-4 antibodies |
WO2017123652A1 (en) | 2016-01-11 | 2017-07-20 | Verndari, Inc. | Microneedle compositions and methods of using same |
WO2017162265A1 (en) * | 2016-03-21 | 2017-09-28 | Biontech Rna Pharmaceuticals Gmbh | Trans-replicating rna |
EP3463445A1 (en) | 2016-06-02 | 2019-04-10 | GlaxoSmithKline Biologicals SA | Zika viral antigen constructs |
EP3518966A1 (en) | 2016-09-29 | 2019-08-07 | GlaxoSmithKline Biologicals S.A. | Compositions and methods of treatment of persistent hpv infection |
GB201616904D0 (en) | 2016-10-05 | 2016-11-16 | Glaxosmithkline Biologicals Sa | Vaccine |
JP6980780B2 (ja) | 2016-10-21 | 2021-12-15 | モデルナティーエックス, インコーポレイテッド | ヒトサイトメガロウイルスワクチン |
WO2018089540A1 (en) | 2016-11-08 | 2018-05-17 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
US10925958B2 (en) | 2016-11-11 | 2021-02-23 | Modernatx, Inc. | Influenza vaccine |
WO2018091540A1 (en) | 2016-11-17 | 2018-05-24 | Glaxosmithkline Biologicals Sa | Zika viral antigen constructs |
US11103578B2 (en) | 2016-12-08 | 2021-08-31 | Modernatx, Inc. | Respiratory virus nucleic acid vaccines |
AU2018229278A1 (en) | 2017-02-28 | 2019-10-17 | Sanofi | Therapeutic RNA |
PL3596041T3 (pl) | 2017-03-15 | 2023-03-06 | Modernatx, Inc. | Związek i kompozycje do dokomórkowego dostarczania środków terapeutycznych |
US11969506B2 (en) | 2017-03-15 | 2024-04-30 | Modernatx, Inc. | Lipid nanoparticle formulation |
MA52262A (fr) | 2017-03-15 | 2020-02-19 | Modernatx Inc | Vaccin à large spectre contre le virus de la grippe |
ES2911186T3 (es) | 2017-03-15 | 2022-05-18 | Modernatx Inc | Formas cristalinas de aminolípidos |
MA47787A (fr) | 2017-03-15 | 2020-01-22 | Modernatx Inc | Vaccin contre le virus respiratoire syncytial |
US11752206B2 (en) | 2017-03-15 | 2023-09-12 | Modernatx, Inc. | Herpes simplex virus vaccine |
US11045540B2 (en) | 2017-03-15 | 2021-06-29 | Modernatx, Inc. | Varicella zoster virus (VZV) vaccine |
WO2018208856A1 (en) | 2017-05-08 | 2018-11-15 | Gritstone Oncology, Inc. | Alphavirus neoantigen vectors |
WO2018213731A1 (en) | 2017-05-18 | 2018-11-22 | Modernatx, Inc. | Polynucleotides encoding tethered interleukin-12 (il12) polypeptides and uses thereof |
ES2952779T3 (es) | 2017-05-18 | 2023-11-06 | Modernatx Inc | ARN mensajero modificado que comprende elementos de ARN funcionales |
EP3638776A1 (en) | 2017-06-14 | 2020-04-22 | Technische Universität Dresden | Methods and means for genetic alteration of genomes utilizing designer dna recombining enzymes |
US20200268666A1 (en) | 2017-06-14 | 2020-08-27 | Modernatx, Inc. | Polynucleotides encoding coagulation factor viii |
US11786607B2 (en) | 2017-06-15 | 2023-10-17 | Modernatx, Inc. | RNA formulations |
MA49693A (fr) | 2017-07-28 | 2020-06-03 | Janssen Vaccines & Prevention Bv | Méthodes et compositions pour assurer l'immunisation contre l'arnrep hétérologue |
CA3073020A1 (en) | 2017-08-16 | 2019-02-21 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
WO2019046809A1 (en) | 2017-08-31 | 2019-03-07 | Modernatx, Inc. | METHODS OF MANUFACTURING LIPID NANOPARTICLES |
US10653767B2 (en) | 2017-09-14 | 2020-05-19 | Modernatx, Inc. | Zika virus MRNA vaccines |
EP3461497A1 (en) | 2017-09-27 | 2019-04-03 | GlaxoSmithKline Biologicals S.A. | Viral antigens |
EP3714048A1 (en) | 2017-11-22 | 2020-09-30 | Modernatx, Inc. | Polynucleotides encoding ornithine transcarbamylase for the treatment of urea cycle disorders |
CA3079543A1 (en) | 2017-11-22 | 2019-05-31 | Modernatx, Inc. | Polynucleotides encoding propionyl-coa carboxylase alpha and beta subunits for the treatment of propionic acidemia |
WO2019104160A2 (en) | 2017-11-22 | 2019-05-31 | Modernatx, Inc. | Polynucleotides encoding phenylalanine hydroxylase for the treatment of phenylketonuria |
EA202091517A1 (ru) | 2017-12-19 | 2020-11-03 | Янссен Сайенсиз Айрлэнд Анлимитед Компани | Способы и устройство для доставки вакцин против вируса гепатита b (hbv) |
EA202091516A1 (ru) | 2017-12-19 | 2020-11-03 | Янссен Сайенсиз Айрлэнд Анлимитед Компани | Способы и композиции для индукции иммунного ответа против вируса гепатита b (hbv) |
US11021692B2 (en) | 2017-12-19 | 2021-06-01 | Janssen Sciences Ireland Unlimited Company | Hepatitis B virus (HBV) vaccines and uses thereof |
AU2018392884B2 (en) | 2017-12-20 | 2021-11-11 | Glaxosmithkline Biologicals Sa | Epstein-Barr Virus antigen constructs |
KR20200118029A (ko) | 2018-01-04 | 2020-10-14 | 아이코닉 테라퓨틱스, 인코포레이티드 | 항-조직 인자 항체, 항체-약물 결합체, 및 관련 방법 |
WO2019136241A1 (en) | 2018-01-05 | 2019-07-11 | Modernatx, Inc. | Polynucleotides encoding anti-chikungunya virus antibodies |
MA54676A (fr) | 2018-01-29 | 2021-11-17 | Modernatx Inc | Vaccins à base d'arn contre le vrs |
WO2019217964A1 (en) | 2018-05-11 | 2019-11-14 | Lupagen, Inc. | Systems and methods for closed loop, real-time modifications of patient cells |
WO2019226650A1 (en) | 2018-05-23 | 2019-11-28 | Modernatx, Inc. | Delivery of dna |
EP3581201A1 (en) | 2018-06-15 | 2019-12-18 | GlaxoSmithKline Biologicals S.A. | Escherichia coli o157:h7 proteins and uses thereof |
US20220184185A1 (en) | 2018-07-25 | 2022-06-16 | Modernatx, Inc. | Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders |
WO2020035609A2 (en) | 2018-08-17 | 2020-02-20 | Glaxosmithkline Biologicals Sa | Immunogenic compositions and uses thereof |
WO2020047201A1 (en) | 2018-09-02 | 2020-03-05 | Modernatx, Inc. | Polynucleotides encoding very long-chain acyl-coa dehydrogenase for the treatment of very long-chain acyl-coa dehydrogenase deficiency |
WO2020056155A2 (en) | 2018-09-13 | 2020-03-19 | Modernatx, Inc. | Polynucleotides encoding branched-chain alpha-ketoacid dehydrogenase complex e1-alpha, e1-beta, and e2 subunits for the treatment of maple syrup urine disease |
MX2021003015A (es) | 2018-09-13 | 2021-07-15 | Modernatx Inc | Polinucleotidos que codifican glucosa-6-fosfatasa para el tratamiento de la glucogenosis. |
MA53615A (fr) | 2018-09-14 | 2021-07-21 | Modernatx Inc | Polynucléotides codant pour le polypeptide a1, de la famille de l'uridine diphosphate glycosyltransférase 1, pour le traitement du syndrome de crigler-najjar |
US20220152225A1 (en) | 2018-09-27 | 2022-05-19 | Modernatx, Inc. | Polynucleotides encoding arginase 1 for the treatment of arginase deficiency |
TW202043256A (zh) | 2019-01-10 | 2020-12-01 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
US11351242B1 (en) | 2019-02-12 | 2022-06-07 | Modernatx, Inc. | HMPV/hPIV3 mRNA vaccine composition |
MX2021010808A (es) * | 2019-03-08 | 2021-12-15 | Massachusetts Inst Technology | Ácido ribonucleico replicón-nanopartículas sinteticas oncolítico y sintético y usos para inmunoterapia de cáncer. |
US20220226438A1 (en) | 2019-05-08 | 2022-07-21 | Astrazeneca Ab | Compositions for skin and wounds and methods of use thereof |
TW202110870A (zh) | 2019-05-30 | 2021-03-16 | 美商葛利史東腫瘤科技公司 | 經修飾之腺病毒 |
US20220296703A1 (en) | 2019-06-18 | 2022-09-22 | Janssen Sciences Ireland Unlimited Company | Cobmination of hepatitis b virus (hbv) vaccines and anti-pd-1 or anti-pd-l1 antibody |
MA56520A (fr) | 2019-06-18 | 2022-04-27 | Janssen Sciences Ireland Unlimited Co | Construction de l'interleukine 12 recombinante et ses utilisations |
WO2020255010A1 (en) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Combination of recombinant interleukin 12 construct and hepatitis b virus (hbv) vaccines |
EP3986460A2 (en) | 2019-06-18 | 2022-04-27 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and anti-pd-1 antibody |
CN114340664A (zh) | 2019-06-18 | 2022-04-12 | 爱尔兰詹森科学公司 | 乙型肝炎病毒(HBV)疫苗和靶向HBV的RNAi的组合 |
US20220305108A1 (en) * | 2019-06-20 | 2022-09-29 | Janssen Sciences Ireland Unlimited Company | Lipid nanoparticle or liposome delivery of hepatitis b virus (hbv) vaccines |
CA3146900A1 (en) | 2019-07-21 | 2021-01-28 | Glaxosmithkline Biologicals Sa | Therapeutic viral vaccine |
AR120080A1 (es) | 2019-09-19 | 2022-02-02 | Modernatx Inc | Compuestos lipídicos de cola ramificada y composiciones para la administración intracelular de agentes terapéuticos |
JP2023519173A (ja) | 2020-03-09 | 2023-05-10 | アークトゥラス・セラピューティクス・インコーポレイテッド | 免疫応答を誘導するための組成物及び方法 |
EP4135761A1 (en) | 2020-04-16 | 2023-02-22 | GlaxoSmithKline Biologicals S.A. | Sars cov-2 spike protein construct |
US20230235298A1 (en) | 2020-06-01 | 2023-07-27 | Modernatx, Inc. | Phenylalanine hydroxylase variants and uses thereof |
US20230234992A1 (en) | 2020-06-05 | 2023-07-27 | Glaxosmithkline Biologicals Sa | Modified betacoronavirus spike proteins |
US20230256090A1 (en) | 2020-06-29 | 2023-08-17 | Glaxosmithkline Biologicals Sa | Adjuvants |
KR20230050328A (ko) | 2020-07-08 | 2023-04-14 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | Hbv에 대한 rna 레플리콘 백신 |
CN116438308A (zh) | 2020-08-06 | 2023-07-14 | 磨石生物公司 | 多表位疫苗盒 |
US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
WO2022104131A1 (en) | 2020-11-13 | 2022-05-19 | Modernatx, Inc. | Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis |
WO2022133230A1 (en) | 2020-12-18 | 2022-06-23 | Janssen Pharmaceuticals, Inc. | Combination therapy for treating hepatitis b virus infection |
CA3171051A1 (en) * | 2020-12-22 | 2022-06-30 | Curevac Ag | Pharmaceutical composition comprising lipid-based carriers encapsulating rna for multidose administration |
WO2022137128A2 (en) | 2020-12-23 | 2022-06-30 | Glaxosmithkline Biologicals Sa | Self-amplifying messenger rna |
EP4267740A1 (en) | 2020-12-28 | 2023-11-01 | Arcturus Therapeutics, Inc. | Transcription activator-like effector nucleases (talens) targeting hbv |
EP4032546A1 (en) | 2021-01-20 | 2022-07-27 | GlaxoSmithKline Biologicals S.A. | Therapeutic viral vaccine |
US11524023B2 (en) | 2021-02-19 | 2022-12-13 | Modernatx, Inc. | Lipid nanoparticle compositions and methods of formulating the same |
WO2022204390A1 (en) | 2021-03-24 | 2022-09-29 | Modernatx, Inc. | Lipid nanoparticles containing polynucleotides encoding phenylalanine hydroxylase and uses thereof |
WO2022204369A1 (en) | 2021-03-24 | 2022-09-29 | Modernatx, Inc. | Polynucleotides encoding methylmalonyl-coa mutase for the treatment of methylmalonic acidemia |
WO2022204380A1 (en) | 2021-03-24 | 2022-09-29 | Modernatx, Inc. | Lipid nanoparticles containing polynucleotides encoding propionyl-coa carboxylase alpha and beta subunits and uses thereof |
WO2022204371A1 (en) | 2021-03-24 | 2022-09-29 | Modernatx, Inc. | Lipid nanoparticles containing polynucleotides encoding glucose-6-phosphatase and uses thereof |
JP2024512026A (ja) | 2021-03-24 | 2024-03-18 | モデルナティエックス インコーポレイテッド | オルニチントランスカルバミラーゼ欠損症の治療を目的とした脂質ナノ粒子及びオルニチントランスカルバミラーゼをコードするポリヌクレオチド |
WO2022200574A1 (en) | 2021-03-26 | 2022-09-29 | Glaxosmithkline Biologicals Sa | Immunogenic compositions |
WO2022248353A1 (en) | 2021-05-24 | 2022-12-01 | Glaxosmithkline Biologicals Sa | Adjuvants |
EP4352247A1 (en) | 2021-06-09 | 2024-04-17 | GlaxoSmithKline Biologicals s.a. | Release assay for determining potency of self-amplifying rna drug product and methods for using |
WO2022266083A2 (en) | 2021-06-15 | 2022-12-22 | Modernatx, Inc. | Engineered polynucleotides for cell-type or microenvironment-specific expression |
WO2022271776A1 (en) | 2021-06-22 | 2022-12-29 | Modernatx, Inc. | Polynucleotides encoding uridine diphosphate glycosyltransferase 1 family, polypeptide a1 for the treatment of crigler-najjar syndrome |
WO2023021427A1 (en) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Freeze-drying of lipid nanoparticles (lnps) encapsulating rna and formulations thereof |
WO2023020994A1 (en) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Novel methods |
WO2023021421A1 (en) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Low-dose lyophilized rna vaccines and methods for preparing and using the same |
WO2023020992A1 (en) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Novel methods |
WO2023020993A1 (en) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Novel methods |
WO2023031855A1 (en) | 2021-09-03 | 2023-03-09 | Glaxosmithkline Biologicals Sa | Substitution of nucleotide bases in self-amplifying messenger ribonucleic acids |
WO2023056044A1 (en) | 2021-10-01 | 2023-04-06 | Modernatx, Inc. | Polynucleotides encoding relaxin for the treatment of fibrosis and/or cardiovascular disease |
WO2023056980A1 (zh) * | 2021-10-09 | 2023-04-13 | 吴可行 | 自复制rna分子设计及其应用 |
WO2023084099A1 (en) | 2021-11-15 | 2023-05-19 | Technische Universität Dresden | Site-specific recombinases for efficient and specific genome editing |
WO2023183909A2 (en) | 2022-03-25 | 2023-09-28 | Modernatx, Inc. | Polynucleotides encoding fanconi anemia, complementation group proteins for the treatment of fanconi anemia |
WO2023198815A1 (en) | 2022-04-14 | 2023-10-19 | Janssen Vaccines & Prevention B.V. | Sequential administration of adenoviruses |
WO2023218420A1 (en) | 2022-05-13 | 2023-11-16 | Janssen Pharmaceuticals, Inc. | Mrna compositions for inducing latent hiv-1 reversal |
WO2023221938A1 (zh) * | 2022-05-16 | 2023-11-23 | 上海行深生物科技有限公司 | 蛋白包裹自复制rna及其制备方法 |
WO2023233290A1 (en) | 2022-05-31 | 2023-12-07 | Janssen Sciences Ireland Unlimited Company | Rnai agents targeting pd-l1 |
WO2023242817A2 (en) | 2022-06-18 | 2023-12-21 | Glaxosmithkline Biologicals Sa | Recombinant rna molecules comprising untranslated regions or segments encoding spike protein from the omicron strain of severe acute respiratory coronavirus-2 |
WO2024026254A1 (en) | 2022-07-26 | 2024-02-01 | Modernatx, Inc. | Engineered polynucleotides for temporal control of expression |
WO2024068545A1 (en) | 2022-09-26 | 2024-04-04 | Glaxosmithkline Biologicals Sa | Influenza virus vaccines |
Family Cites Families (115)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6090406A (en) | 1984-04-12 | 2000-07-18 | The Liposome Company, Inc. | Potentiation of immune responses with liposomal adjuvants |
US5140086A (en) | 1988-11-25 | 1992-08-18 | Weyerhaeuser Company | Isocyanate modified cellulose products and method for their manufacture |
US6867195B1 (en) | 1989-03-21 | 2005-03-15 | Vical Incorporated | Lipid-mediated polynucleotide administration to reduce likelihood of subject's becoming infected |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5279833A (en) | 1990-04-04 | 1994-01-18 | Yale University | Liposomal transfection of nucleic acids into animal cells |
US5693535A (en) | 1992-05-14 | 1997-12-02 | Ribozyme Pharmaceuticals, Inc. | HIV targeted ribozymes |
US5750390A (en) | 1992-08-26 | 1998-05-12 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for treatment of diseases caused by expression of the bcl-2 gene |
AU4528493A (en) | 1992-06-04 | 1994-01-04 | Regents Of The University Of California, The | In vivo gene therapy with intron-free sequence of interest |
WO1994002595A1 (en) | 1992-07-17 | 1994-02-03 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for treatment of animal diseases |
WO1994027435A1 (en) | 1993-06-01 | 1994-12-08 | Life Technologies, Inc. | Genetic immunization with cationic lipids |
US6015686A (en) | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
AU727923B2 (en) * | 1995-09-27 | 2001-01-04 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Production of infectious respiratory syncytial virus from cloned nucleotide sequences |
CA2259179C (en) | 1996-07-03 | 2008-09-23 | University Of Pittsburgh | Emulsion formulations for hydrophilic active agents |
WO1998010748A1 (en) | 1996-09-13 | 1998-03-19 | The School Of Pharmacy | Liposomes |
US7384923B2 (en) | 1999-05-14 | 2008-06-10 | Lipoxen Technologies Limited | Liposomes |
US6395302B1 (en) | 1996-11-19 | 2002-05-28 | Octoplus B.V. | Method for the preparation of microspheres which contain colloidal systems |
DE69841002D1 (de) | 1997-05-14 | 2009-09-03 | Univ British Columbia | Hochwirksame verkapselung von nukleinsäuren in lipidvesikeln |
US6060308A (en) | 1997-09-04 | 2000-05-09 | Connaught Laboratories Limited | RNA respiratory syncytial virus vaccines |
US6009406A (en) | 1997-12-05 | 1999-12-28 | Square D Company | Methodology and computer-based tools for re-engineering a custom-engineered product line |
US6432925B1 (en) | 1998-04-16 | 2002-08-13 | John Wayne Cancer Institute | RNA cancer vaccine and methods for its use |
US6517842B1 (en) | 1998-06-29 | 2003-02-11 | The United States Of America As Represented By The Secretary Of The Army | Marburg virus vaccines |
EP1541690A3 (en) | 1999-09-09 | 2005-07-27 | CureVac GmbH | Transfer of mRNA using polycationic compounds |
EP1222289B1 (en) | 1999-10-20 | 2008-04-16 | The Johns Hopkins University School Of Medicine | Chimeric immunogenic compositions and nucleic acids encoding them |
US8541008B2 (en) * | 1999-11-19 | 2013-09-24 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Pharmaceutical compositions and methods to vaccinate against candidiasis |
US20030212022A1 (en) | 2001-03-23 | 2003-11-13 | Jean-Marie Vogel | Compositions and methods for gene therapy |
US7149665B2 (en) | 2000-04-03 | 2006-12-12 | Browzwear International Ltd | System and method for simulation of virtual wear articles on virtual models |
EP1287015A1 (en) | 2000-04-18 | 2003-03-05 | Human Genome Sciences, Inc. | Extracellular matrix polynucleotides, polypeptides, and antibodies |
ATE440861T1 (de) | 2000-07-03 | 2009-09-15 | Novartis Vaccines & Diagnostic | Immunisierung gegen chlamydia pneumoniae |
AU2001290520A1 (en) | 2000-08-01 | 2002-02-13 | The Johns Hokpins University | Intercellular transport protein linked to an antigen as a molecular vaccine |
CA2421683C (en) | 2000-09-28 | 2009-09-15 | Chiron Corporation | Microparticles for delivery of the heterologous nucleic acids |
MXPA03003690A (es) | 2000-10-27 | 2004-05-05 | Chiron Spa | Acidos nucleicos y proteinas de los grupos a y b de estreptococos. |
WO2002079239A2 (en) | 2001-01-31 | 2002-10-10 | U.S. Army Medical Research Institute Of Infectious Diseases | Chimeric filovirus glycoprotein |
WO2002061113A2 (en) | 2001-02-01 | 2002-08-08 | The Johns Hopkins University | Nucleic acid derived vaccine that encodes an antigen linked to a polypeptide that promotes antigen presentation |
US20030040498A1 (en) | 2001-03-14 | 2003-02-27 | Ansardi David Calvert | Oncolytic RNA replicons |
US20030077251A1 (en) | 2001-05-23 | 2003-04-24 | Nicolas Escriou | Replicons derived from positive strand RNA virus genomes useful for the production of heterologous proteins |
EP2305699B1 (de) | 2001-06-05 | 2014-08-13 | CureVac GmbH | Stabilisierte mRNA mit erhöhtem G/C-Gehalt und optimierter Codon Usage für die Impfung gegen Schlafkrankheit, Leishmaniose und Toxoplasmose |
CA2458854A1 (en) | 2001-08-31 | 2003-03-06 | Chiron Srl | Helicobacter pylori vaccination |
DE60233061D1 (de) * | 2001-09-06 | 2009-09-03 | Alphavax Inc | Alphavirus replikon-vektorsysteme |
AU2003211103A1 (en) | 2002-02-13 | 2003-09-04 | Northeastern University | Intracellular delivery of therapeutic agents |
DE10207177A1 (de) | 2002-02-19 | 2003-09-04 | Novosom Ag | Fakultativ kationische Lipide |
ATE485031T1 (de) | 2002-06-28 | 2010-11-15 | Protiva Biotherapeutics Inc | Verfahren und vorrichtung zur herstellung von liposomen |
CA2498777C (en) | 2002-09-13 | 2015-01-13 | Replicor, Inc. | Non-sequence complementary antiviral oligonucleotides |
DE60333035D1 (de) | 2002-12-23 | 2010-07-29 | Vical Inc | Impfstoffe gegen infektionen mit dem humanen zytomegalivirus auf grundlage von codonoptimierten polynukleotiden |
WO2004069148A2 (en) | 2003-02-04 | 2004-08-19 | Bar-Ilan University | Snornai-small nucleolar rna degradation by rna interference in trypanosomatids |
US7731967B2 (en) | 2003-04-30 | 2010-06-08 | Novartis Vaccines And Diagnostics, Inc. | Compositions for inducing immune responses |
US20070042979A1 (en) | 2003-05-30 | 2007-02-22 | Junichi Yano | Oligonucleic acid-bearing composite and pharmaceutical composition containing the composite |
US20100255002A1 (en) | 2003-06-26 | 2010-10-07 | Chiron Corporation | Immunogenic compositions for chlamydia trachomatis |
US7368537B2 (en) * | 2003-07-15 | 2008-05-06 | Id Biomedical Corporation Of Quebec | Subunit vaccine against respiratory syncytial virus infection |
EP2567693B1 (en) | 2003-07-16 | 2015-10-21 | Protiva Biotherapeutics Inc. | Lipid encapsulated interfering RNA |
EP1648500B1 (en) | 2003-07-31 | 2014-07-09 | Novartis Vaccines and Diagnostics, Inc. | Immunogenic compositions for streptococcus pyogenes |
US7303881B2 (en) | 2004-04-30 | 2007-12-04 | Pds Biotechnology Corporation | Antigen delivery compositions and methods of use |
GB0410866D0 (en) | 2004-05-14 | 2004-06-16 | Chiron Srl | Haemophilius influenzae |
US20050266550A1 (en) | 2004-05-18 | 2005-12-01 | Alphavax, Inc. | TC-83-derived alphavirus vectors, particles and methods |
AU2005248361B2 (en) | 2004-05-18 | 2010-03-11 | Vical Incorporated | Influenza virus vaccine composition and methods of use |
EP2811027A1 (en) | 2004-05-21 | 2014-12-10 | Novartis Vaccines and Diagnostics, Inc. | Alphavirus vectors for RSV and PIV vaccines |
US7799565B2 (en) | 2004-06-07 | 2010-09-21 | Protiva Biotherapeutics, Inc. | Lipid encapsulated interfering RNA |
US7745651B2 (en) | 2004-06-07 | 2010-06-29 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods of use |
US20060051405A1 (en) * | 2004-07-19 | 2006-03-09 | Protiva Biotherapeutics, Inc. | Compositions for the delivery of therapeutic agents and uses thereof |
WO2006038129A2 (en) | 2004-10-01 | 2006-04-13 | Novartis Vaccines And Diagnostics Srl | Hepatitis c virus replication system |
ES2434029T3 (es) * | 2004-11-15 | 2013-12-13 | Novartis Vaccines And Diagnostics, Inc. | Composiciones inmunogénicas que contiene antígeno de antrax, micropartículas de polímero biodegradable, y adyuvante inmunológico que contiene polinucleótido |
CN101203529A (zh) | 2005-02-18 | 2008-06-18 | 诺华疫苗和诊断公司 | 来自脑膜炎/脓毒症相关性大肠杆菌的蛋白质和核酸 |
SG160329A1 (en) | 2005-02-18 | 2010-04-29 | Novartis Vaccines & Diagnostic | Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli |
WO2006092607A1 (en) | 2005-03-02 | 2006-09-08 | The Secretary Of State For Defence | Pharmaceutical composition |
EP1871888A4 (en) | 2005-03-30 | 2013-08-21 | Novartis Vaccines & Diagnostic | HAEMOPHILUS INFLUENZAE TYPE B |
US7618393B2 (en) | 2005-05-03 | 2009-11-17 | Pharmajet, Inc. | Needle-less injector and method of fluid delivery |
WO2006138004A2 (en) | 2005-05-12 | 2006-12-28 | Novartis Vaccines And Diagnostics, Inc. | Immunogenic compositions for chlamydia trachomatis |
US8703095B2 (en) | 2005-07-07 | 2014-04-22 | Sanofi Pasteur S.A. | Immuno-adjuvant emulsion |
DK2578685T3 (da) | 2005-08-23 | 2019-06-03 | Univ Pennsylvania | Rna indeholende modificerede nukleosider og fremgangsmåder til anvendelse deraf |
JP2009511636A (ja) | 2005-10-18 | 2009-03-19 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス, インコーポレイテッド | アルファウイルスレプリコン粒子による粘膜免疫および全身免疫 |
JP2007112768A (ja) | 2005-10-24 | 2007-05-10 | Kyoto Univ | 肝指向性リポソーム組成物 |
JP2009515831A (ja) | 2005-10-25 | 2009-04-16 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル | ペスト菌(Yersiniapestis)抗原を含む組成物 |
US7915399B2 (en) | 2006-06-09 | 2011-03-29 | Protiva Biotherapeutics, Inc. | Modified siRNA molecules and uses thereof |
EP2064230A2 (en) | 2006-08-16 | 2009-06-03 | Novartis AG | Immunogens from uropathogenic escherichia coli |
CA2689042A1 (en) | 2007-02-16 | 2008-08-28 | Merck & Co., Inc. | Compositions and methods for potentiated activity of biologicaly active molecules |
US8877206B2 (en) | 2007-03-22 | 2014-11-04 | Pds Biotechnology Corporation | Stimulation of an immune response by cationic lipids |
AU2008247488B2 (en) | 2007-05-04 | 2014-02-27 | Marina Biotech, Inc. | Amino acid lipids and uses thereof |
DE102007029471A1 (de) | 2007-06-20 | 2008-12-24 | Novosom Ag | Neue fakultativ kationische Sterole |
GB0714963D0 (en) | 2007-08-01 | 2007-09-12 | Novartis Ag | Compositions comprising antigens |
GB0717187D0 (en) | 2007-09-04 | 2007-10-17 | Novartis Ag | Compositions comprising yersinia pestis antigens |
US20090162395A1 (en) | 2007-09-26 | 2009-06-25 | Crowe Jr James E | Vaccine for rsv and mpv |
WO2009079185A2 (en) | 2007-11-26 | 2009-06-25 | Novartis Vaccines And Diagnostics, Inc. | Methods of generating alphavirus particles |
WO2009111088A2 (en) | 2008-01-02 | 2009-09-11 | The Johns Hopkins University | Antitumor immunization by liposomal delivery of vaccine to the spleen |
WO2009086558A1 (en) | 2008-01-02 | 2009-07-09 | Tekmira Pharmaceuticals Corporation | Improved compositions and methods for the delivery of nucleic acids |
ITMI20081249A1 (it) | 2008-07-09 | 2010-01-09 | Novartis Vaccines & Diagnostic | Immunogeni di escherichia coli con solubilità migliorata. |
US20110110857A1 (en) | 2008-03-06 | 2011-05-12 | Roberto Petracca | Mutant forms of chlamydia htra |
WO2009127060A1 (en) | 2008-04-15 | 2009-10-22 | Protiva Biotherapeutics, Inc. | Novel lipid formulations for nucleic acid delivery |
WO2009127230A1 (en) | 2008-04-16 | 2009-10-22 | Curevac Gmbh | MODIFIED (m)RNA FOR SUPPRESSING OR AVOIDING AN IMMUNOSTIMULATORY RESPONSE AND IMMUNOSUPPRESSIVE COMPOSITION |
WO2009132206A1 (en) | 2008-04-25 | 2009-10-29 | Liquidia Technologies, Inc. | Compositions and methods for intracellular delivery and release of cargo |
US20100040650A1 (en) * | 2008-05-30 | 2010-02-18 | Crowe Jr James E | Virus-Like paramyxovirus particles and vaccines |
EP2130912A1 (en) | 2008-06-04 | 2009-12-09 | Institut für Viruskrankeiten und Immunprophylaxe | Pestivirus replicons providing an RNA-based viral vector system |
CL2008002322A1 (es) | 2008-08-07 | 2009-06-05 | Univ Concepcion | Formulacion farmaceutica veterinaria que comprende un sistema vectorial viral constituido por una particula recombinante de arn que codifica una cu/zn superoxido dismutasa de la bacteria patogena de bovinos brucella abortus, y al menos un alfavirus arn perteneciente a la familia del virus semliki forest (sfv), util como vacuna. |
US9139554B2 (en) | 2008-10-09 | 2015-09-22 | Tekmira Pharmaceuticals Corporation | Amino lipids and methods for the delivery of nucleic acids |
EP2367844A4 (en) | 2008-11-18 | 2012-08-01 | Ligocyte Pharmaceuticals Inc | RSV-F VLP AND MANUFACTURING METHOD AND METHOD OF USE THEREOF |
EP3263128A3 (en) | 2009-04-14 | 2018-01-24 | GlaxoSmithKline Biologicals S.A. | Compositions for immunising against staphylococcus aureus |
CA2767127A1 (en) | 2009-07-01 | 2011-01-06 | Protiva Biotherapeutics, Inc. | Novel lipid formulations for delivery of therapeutic agents to solid tumors |
US20120100207A1 (en) | 2009-07-02 | 2012-04-26 | Konica Minolta Holdings, Inc. | Process for producing liposomes by two-step emulsification method utilizing outer aqueous phase containing specific dispersing agent, process for producing liposome dispersion or dry powder thereof using the process for producing liposomes, and liposome dispersion or dry powder thereof produced thereby |
EP2451475A2 (en) | 2009-07-06 | 2012-05-16 | Novartis AG | Self replicating rna molecules and uses thereof |
WO2011008974A2 (en) * | 2009-07-15 | 2011-01-20 | Novartis Ag | Rsv f protein compositions and methods for making same |
US8277919B2 (en) | 2009-07-23 | 2012-10-02 | VMO Systems, Inc. | Reflective coating for an optical disc |
CN102695525B (zh) | 2009-07-31 | 2016-01-20 | 埃泽瑞斯公司 | 用于蛋白质表达的具有未修饰和修饰核苷酸的组合的rna |
WO2011140627A1 (en) * | 2009-11-04 | 2011-11-17 | The University Of British Columbia | Nucleic acid-containing lipid particles and related methods |
US20110112353A1 (en) | 2009-11-09 | 2011-05-12 | Circulite, Inc. | Bifurcated outflow cannulae |
PT2506857T (pt) | 2009-12-01 | 2018-05-14 | Translate Bio Inc | Entrega de arnm para o acréscimo de proteínas e enzimas em doenças genéticas humanas |
SG181904A1 (en) | 2009-12-23 | 2012-07-30 | Novartis Ag | Lipids, lipid compositions, and methods of using them |
US9770463B2 (en) | 2010-07-06 | 2017-09-26 | Glaxosmithkline Biologicals Sa | Delivery of RNA to different cell types |
ES2770335T3 (es) | 2010-07-06 | 2020-07-01 | Glaxosmithkline Biologicals Sa | Administración de ARN para desencadenar múltiples vías inmunológicas |
PL2590626T3 (pl) | 2010-07-06 | 2016-04-29 | Glaxosmithkline Biologicals Sa | Liposomy z lipidami o korzystnej wartości pka do dostarczania rna |
CA2804494A1 (en) | 2010-07-06 | 2012-01-12 | Novartis Ag | Virion-like delivery particles for self-replicating rna molecules |
WO2012006369A2 (en) | 2010-07-06 | 2012-01-12 | Novartis Ag | Immunisation of large mammals with low doses of rna |
MX343410B (es) | 2010-07-06 | 2016-11-04 | Novartis Ag * | Emulsiones cationicas de agua en aceite. |
ES2727583T3 (es) | 2010-08-31 | 2019-10-17 | Glaxosmithkline Biologicals Sa | Lípidos adecuados para la administración liposómica de ARN que codifica proteínas |
HRP20221048T1 (hr) | 2010-08-31 | 2022-11-11 | Glaxosmithkline Biologicals Sa | Mali liposomi za isporuku rna koja kodira imunogen |
LT3981427T (lt) | 2010-08-31 | 2022-08-10 | Glaxosmithkline Biologicals S.A. | Pegilintos liposomos, skirtos imunogeną koduojančios rnr pristatymui |
EP2729126B1 (en) | 2011-07-06 | 2020-12-23 | GlaxoSmithKline Biologicals SA | Liposomes having useful n:p ratio for delivery of rna molecules |
RU2628705C2 (ru) | 2011-08-31 | 2017-08-21 | Новартис Аг | Пегилированные липосомы для доставки кодирующей иммуноген рнк |
-
2011
- 2011-07-06 CA CA2804494A patent/CA2804494A1/en active Pending
- 2011-07-06 JP JP2013518813A patent/JP6061849B2/ja active Active
- 2011-07-06 PT PT117413484T patent/PT2590676T/pt unknown
- 2011-07-06 PT PT212041552T patent/PT4005592T/pt unknown
- 2011-07-06 EP EP16184271.1A patent/EP3115061A1/en not_active Withdrawn
- 2011-07-06 PL PL11741348T patent/PL2590676T3/pl unknown
- 2011-07-06 HU HUE11741348A patent/HUE031485T2/en unknown
- 2011-07-06 SI SI201130994A patent/SI2590676T1/sl unknown
- 2011-07-06 ES ES21204155T patent/ES2934240T3/es active Active
- 2011-07-06 BR BR112013000392A patent/BR112013000392B8/pt active IP Right Grant
- 2011-07-06 CN CN201610906410.1A patent/CN106421773A/zh active Pending
- 2011-07-06 PL PL21204155.2T patent/PL4005592T3/pl unknown
- 2011-07-06 SI SI201132073T patent/SI4005592T1/sl unknown
- 2011-07-06 MX MX2013000089A patent/MX342608B/es active IP Right Grant
- 2011-07-06 AU AU2011276232A patent/AU2011276232B2/en active Active
- 2011-07-06 HU HUE21204155A patent/HUE060788T2/hu unknown
- 2011-07-06 WO PCT/US2011/043103 patent/WO2012006376A2/en active Application Filing
- 2011-07-06 FI FIEP21204155.2T patent/FI4005592T3/fi active
- 2011-07-06 RS RS20160879A patent/RS55260B1/sr unknown
- 2011-07-06 LT LTEP11741348.4T patent/LT2590676T/lt unknown
- 2011-07-06 HR HRP20221522TT patent/HRP20221522T1/hr unknown
- 2011-07-06 RU RU2013104890/15A patent/RU2013104890A/ru unknown
- 2011-07-06 DK DK11741348.4T patent/DK2590676T3/en active
- 2011-07-06 ES ES11741348.4T patent/ES2600892T3/es active Active
- 2011-07-06 US US13/808,089 patent/US11291635B2/en active Active
- 2011-07-06 EP EP22200367.5A patent/EP4180057A1/en active Pending
- 2011-07-06 EP EP21204155.2A patent/EP4005592B1/en active Active
- 2011-07-06 EP EP11741348.4A patent/EP2590676B1/en not_active Revoked
- 2011-07-06 CN CN201180033479.3A patent/CN103052400B/zh active Active
- 2011-07-06 RS RS20221148A patent/RS63817B1/sr unknown
- 2011-07-06 LT LTEP21204155.2T patent/LT4005592T/lt unknown
-
2016
- 2016-10-10 CY CY20161101007T patent/CY1118080T1/el unknown
- 2016-10-17 HR HRP20161352TT patent/HRP20161352T1/hr unknown
- 2016-10-27 SM SM201600386T patent/SMT201600386B/it unknown
-
2022
- 2022-03-01 US US17/683,931 patent/US20220192997A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RS55260B1 (sr) | Čestice slične virionu za dopremanje samoreplicirajućih rnk molekula | |
IL231761A0 (en) | Recombinant polycistronic RNA molecules that replicate themselves | |
PL2563508T3 (pl) | Cząstka przenosząca | |
EP2719190B8 (en) | Spatially-segmented content delivery | |
GB201010557D0 (en) | RNA molecules and uses thereof | |
EP2409240A4 (en) | MEDIA DELIVERY SYSTEM WITH VARIABLE SPEED | |
ZA201006260B (en) | Delivery particle | |
ZA201005524B (en) | Delivery particle | |
EP2512522A4 (en) | PARTICULARS FOR THE DELIVERY OF SEVERAL ACTIVE SUBSTANCES | |
ZA201100622B (en) | Delivery particle | |
IL215455A0 (en) | Methods and materials for delivering molecules | |
EP2776056A4 (en) | NEW COMPOSITION FOR GENETIC RELIEF | |
ZA201309001B (en) | Polymer particles | |
EP2699670A4 (en) | PARTICLES SYNTHETIZED FROM CELLS | |
ZA201106651B (en) | Composition comprising delivery particles | |
EP2721633A4 (en) | STABILIZED NANO CRYSTALS | |
IL226170A0 (en) | Compositions and methods for delivery of nucleic acids based on nanopolymers | |
EP2707756A4 (en) | REMOVAL OF REAL AMPLITUDE LAYERS IN FRACTURED MEDIA | |
EP2707480A4 (en) | PSEUDOVIRAL PARTICLES (VLPs) AND PREPARATION METHOD THEREOF | |
GB201112754D0 (en) | Particulate material delivery method and system | |
PT2550305T (pt) | Processo contínuo para preparar partículas de polifluoroacrilato | |
ZA201303254B (en) | Small viral rna molecules and uses thereof | |
EP2616813A4 (en) | HOST-SUPPORTED GENETIC BIOSENSORS | |
GB0903562D0 (en) | RNA molecules | |
GB201018544D0 (en) | Monodisperse polymer particles |